Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer

• Published in: Oncology letters Vol. 10; no. 4; pp. 2598 - 2602
• Main Authors: SURMELI, ZEKI GOKHAN, VAROL, UMUT, CAKAR, BURCU, DEGIRMENCI, MUSTAFA, ARSLAN, CAGATAY, PISKIN, GONUL DEMIR, ZENGEL, BAHA, KARACA, BURCAK, SANLI, ULUS ALI, USLU, RUCHAN
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.10.2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Breast cancer; Cancer therapies; Capecitabine; Chemotherapy; Chemotherapy, Combination; Development and progression; Disease control; Docetaxel; Drug therapy; Endocrine therapy; Health aspects; Lymphatic system; maintenance therapy; Metastasis; Neutropenia; Oncology; Patients; Quality of life; Response rates; Turkey; capecitabine; breast cancer; maintenance therapy; docetaxel
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2015.3546

The present study aimed to analyze the efficacy of maintenance therapy with single agent capecitabine for human epidermal growth factor receptor (HER2) negative metastatic breast cancer (MBC) patients following disease control with 6 cycles of docetaxel plus capecitabine chemotherapy as the first-line treatment. As an initial treatment, 6 cycles of docetaxel plus capecitabine followed by maintenance therapy with capecitabine were administered. A total of 55 patients received combination therapy and 48 patients proceeded to maintenance therapy: Of these, 32 patients (66.7%) were postmenopausal and 37 (77.1%) had estrogen and progesterone receptor positive disease. The median progression-free survival rate with maintenance therapy was 5.5 months (95% CI, 0-11.4 months) and the median overall survival (OS) was 26.6 months (95% CI, 21.8-30.1 months). The use of maintenance therapy improved previous responses in 4 patients (8.3%; 2 partial and 2 complete responses) and 32 patients (66.7%) had stable disease. The median number of maintenance therapy cycles applied was 6.5 (range 1-28, total 441). The observation of side effects, including grade 3/4 neutropenia, febrile neutropenia and fatigue was more common during combination therapy. The results of the present study indicate that maintenance with single agent capecitabine therapy is an effective and tolerable treatment option for HER2 negative MBC patients in which disease control with 6 cycles of docetaxel plus capecitabine chemotherapy is achieved in the first-line setting.